MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03165nam a22005537a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
201231s20212021 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1175-3277 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/s40256-020-00459-1 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/s40256-020-00459-1 [pii] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
33369719 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. [Review] |
| 251 ## - Source |
|---|
| Source |
American Journal of Cardiovascular Drugs. 21(5):499-512, 2021 Sep. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Am J Cardiovasc Drugs. 21(5):499-512, 2021 Sep. |
| 252 ## - Abbreviated Source |
|---|
| Former abbreviated source |
Am J Cardiovasc Drugs. 2020 Dec 28 |
| 253 ## - Journal Name |
|---|
| Journal name |
American journal of cardiovascular drugs : drugs, devices, and other interventions |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2021 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2022 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
aheadofprint |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
ppublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2020-12-31 |
| 268 ## - Previous citation |
|---|
| -- |
American Journal of Cardiovascular Drugs. 2020 Dec 28 |
| 269 ## - Original dates |
|---|
| Original fiscal year |
FY2021 |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online from MWHC library: 2001 - 2009 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials, and COLCORONA trial which will shed light on its utility in COVID-19. Our aim is to review the CV use of colchicine beyond pericardial diseases, as well as CV outcomes of the available gout therapies, including allopurinol and febuxostat. The CARES trial and its surrounding controversies, which lead to the US FDA 'black box' warning on febuxostat, in addition to the recent FAST trial which contradicts this and finds febuxostat to be non-inferior, are discussed in this paper. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Cardiovascular Diseases/co [Complications] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Colchicine/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Gout Suppressants/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Gout/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Gout/et [Etiology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Colchicine/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Febuxostat/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Febuxostat/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Gout Suppressants/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Hyperuricemia/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Hyperuricemia/et [Etiology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pandemics |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Union Memorial Hospital |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Ghosh, Raktim K |
| 790 ## - Authors |
|---|
| All authors |
Bandyopadhyay D, Deedwania P, Fonarow GC, Ghosh RK, Gupta M, Hajra A, Kaul S, Klein A, Lavie CJ, Mamas M, Roddy E |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1007/s40256-020-00459-1">https://dx.doi.org/10.1007/s40256-020-00459-1</a> |
| Public note |
https://dx.doi.org/10.1007/s40256-020-00459-1 |
| 858 ## - ORCID |
|---|
| ORCID text |
Ghosh, Raktim K |
| Orcid |
<a href="http://orcid.org/0000-0002-8294-3488">http://orcid.org/0000-0002-8294-3488</a> |
| Name |
http://orcid.org/0000-0002-8294-3488 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
